The Neurodegenerative Diseases group has developed an extensive work during 2022 fostering collaboration and resources to better understand the underlying causes of Parkinson’s disease. The group is coordinating the strategic project Aligning Science Across Parkinson’s (ASAP), an international project granted with 11 million USD. The international research groups involved are based in Europe, United States of America and Australia. In addition, the group is participating in other private and public projects that combine the scientific and clinical research. The group has published twenty publications, most of them in quartile 1, and participated in more than 30 international scientific meetings in the field of neurodegenerative Diseases and movement disorders.

Group Leader
Miquel Vila Bover

Principal Investigator (PI)
Marta Martínez Vicente, Jordi Bové Badell, Jorge Hernández Vara, Ariadna Laguna Tuset, Oriol de Fabregues-Boixar Nebot

Researchers
Daniela Samaniego Toro, David Ramos Vicente, Helena Xicoy Cortada, Javier Hoyo Pérez, Núria Peñuelas Peñarroya, Marta González Sepúlveda, Thais Cuadros Arasa

PhD Students
Silvia Enríquez Calzada, Tsakogias Iraklis, Alba Nicolau Vera, Anna Garcia Serra, Camille Guillard Sirieix, Eddie Pradas Gracia, Gerard Roch Alba, Joana Margalida Cladera Sastre, Maria Camprodon Gomez, Marina Lorente Picón, Marta Montpeyó Garcia-Moreno

Lab Technicians
Annabelle Parent, Jordi Riera Heredia, Maria Belen Garcé Rivarola, Pablo Castillo Sánchez, Maria Sellés Altés

17

PUBLICATIONS

35.3%

%Q1

108

IMPACT FACTOR

6.37

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Miquel-Rio L, Alarcon-Aris D, Torres-Lopez M, Coppola-Segovia V, Pavia-Collado R, Paz V, Ruiz-Bronchal E, Campa L, Casal C, Montefeltro A, Vila M, Artigas F, Revilla R, Bortolozzi A
Human alpha-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy
Transl Psychiatry. 2022 Feb 24;12(1):79.
DOI: doi: 10.1038/s41398-022-01842-z.
IF: 7.99

Irazoki A, Martinez-Vicente M, Aparicio P, Aris C, Alibakhshi E, Rubio-Valera M, Castellanos J, Lores L, Palacin M, Guma A, Zorzano A, Sebastian D
Coordination of mitochondrial and lysosomal homeostasis mitigates inflammation and muscle atrophy during aging
Aging Cell. 2022 Apr;21(4):e13583.
DOI: doi: 10.1111/acel.13583. Epub 2022 Mar 9.
IF: 11.01

Teil M, Dovero S, Bourdenx M, Arotcarena ML, Camus S, Porras G, Thiolat ML, Trigo-Damas I, Perier C, Estrada C, Garcia-Carrillo N, Morari M, Meissner WG, Herrero MT, Vila M, Obeso JA, Bezard E, Dehay B
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology
Brain. 2022 Apr 29;145(3):1001-1017.
DOI: doi: 10.1093/brain/awab374.
IF: 15.255

Gonzalez-Sepulveda M, Omar MY, Hamdon S, Ma G, Rosell-Vilar S, Raivio N, Abass D, Martinez-Rivas A, Vila M, Giraldo J, Carrascal M, Abian J, Gil C, Sabria J, Ortiz J, Moreno-Delgado D
Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase
Neuropharmacology. 2022 Jul 1;212:109058.
DOI: doi: 10.1016/j.neuropharm.2022.109058.
IF: 5.273

Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, Castillo-Sanchez P, Carnicer-Caceres C, Arranz-Amo JA, Castillo-Ribelles L, Pradas E, Casas J, Vila M, Martinez-Vicente M
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology
NPJ Parkinsons Dis. 2022 Oct 6;8(1):126.
DOI: doi: 10.1038/s41531-022-00397-6.
IF: 9.304

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson’s disease
Principal Investigator: Miquel Vila
Agency: Aligning Science Across Parkinson’s (ASAP, USA)
Funding: $1,485,066
Period: 2021-2024

Molecular mechanisms of neuromelanin-linked neurodegeneration in Parkinson’s disease and brain aging
Principal Investigator: Miquel Vila
Agency: Spanish Ministry of Science and Innovation (MICINN, Spain)
Funding: 332,750 €
Period: 2021 - 2024

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies
Principal Investigator: Marta Martinez-Vicente, Jorge Hernandez-Vara
Agency: Instituto de Salud Carlos III-Fondo de Investigación Sanitaria (Spain)
Funding: 245,932.5 €
Period: 2021 - 2023

Targeting neuromelanin-linked neuronal dysfunction and degeneration in ageing and Parkinson’s disease using a combined imaging and brain stimulation approach
Principal Investigator: Miquel Vila
Agency: EU Joint Programme
Funding: 739,979.19 €
Period: 2021 - 2023

The gut-brain axis in Parkinson’s disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches
Principal Investigator: Ariadna Laguna
Agency: LaCaixa Foundation
Funding: 305,100 €
Period: 2019 - 2022

eCOREs